Prescription ·Strong evidence ·Reviewed May 2026
Prescription non-benzodiazepine sedative-hypnotic (Schedule IV controlled substance) approved for the short-term treatment of insomnia. Selectively targets GABA-A receptors containing the alpha-1 subunit, providing sleep-inducing effects with less muscle relaxation and anticonvulsant activity than benzodiazepines. Associated with complex sleep behaviors (sleepwalking, sleep-driving). Lower doses recommended for women due to slower clearance. Dosage must be determined by your prescribing physician.
The bottom line
Evidence rating strong. Most-documented uses: rapid sleep onset, reduced sleep latency, short-term insomnia treatment. 12 sources indexed (1997–2024), with 4 interaction records on file.
Core mechanism
Selectively binds to GABA-A receptors containing the alpha-1 subunit (BZ1 receptor subtype), which mediates sedation and hypnotic effects. This selectivity distinguishes it from benzodiazepines, which bind non-selectively to alpha-1, alpha-2, alpha-3, and alpha-5 GABA-A receptor subtypes.9
Take on an empty stomach immediately before bedtime. Food delays absorption and reduces peak plasma levels. Allow at least 7–8 hours before planned awakening. Lower doses recommended for women.3,9
Both zolpidem and valerian act on GABA-A receptors. Combined use can cause excessive CNS depression, over-sedation, and next-day impairment.
Recommendation: Avoid combining zolpidem with valerian root. If sleep support is needed beyond zolpidem, discuss with your prescriber rather than adding herbal sedatives.
Both zolpidem and melatonin promote sleep through different mechanisms. Combined use may cause excessive sedation but is sometimes used clinically under medical supervision.
Recommendation: If using melatonin with zolpidem, use very low melatonin doses (0.5mg). Excessive sedation, dizziness, and morning grogginess can occur. Discuss with your prescriber.
Alcohol adds to zolpidem's hypnotic and psychomotor-impairing effects. Controlled testing showed both zolpidem and alcohol impaired cognitive and motor performance, and real-world reports link zolpidem to confusion, amnesia, sleep-driving, and complex behaviors. Alcohol increases the danger of these behaviors and next-day impairment.
Recommendation: Do not drink alcohol on nights you take zolpidem. Do not take zolpidem after drinking, even if you feel awake. Seek help if sleepwalking, sleep-driving, severe confusion, or unusual behavior occurs.
St. John's Wort can induce CYP3A4 and P-glycoprotein, while zolpidem is partly cleared through CYP3A-mediated metabolism. The combination may reduce zolpidem exposure and make sleep benefit less reliable; stopping St. John's Wort may reverse induction and increase zolpidem effect. Product hyperforin content makes the size of the interaction unpredictable.
Recommendation: Avoid changing St. John's Wort use while taking zolpidem unless your prescriber agrees. Do not raise zolpidem on your own if it seems weaker after starting the herb. Watch for stronger sedation if the herb is stopped.
Numbered references. Citations throughout the page link here.
Landmark network meta-analysis of 154 trials found zolpidem among the most effective drugs for acute insomnia treatment, significantly improving sleep onset latency and total sleep time; however, long-term data were limited.
Systematic review and meta-analysis found zolpidem use was significantly associated with increased risk of suicidal ideation and suicide attempts, highlighting the need for careful screening and monitoring in patients prescribed zolpidem.
Zhou M, Tang J, Li S et al.. Orexin dual receptor antagonists, zolpidem, zopiclone, eszopiclone, and cognitive research: A comprehensive dose-response meta-analysis. Frontiers in human neuroscience. 2022
Bomalaski MN, Claflin ES, Townsend W et al.. Zolpidem for the Treatment of Neurologic Disorders: A Systematic Review. JAMA neurology. 2017
Park SM, Ryu J, Lee DR et al.. Zolpidem use and risk of fractures: a systematic review and meta-analysis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2016
Nowell PD, Mazumdar S, Buysse DJ et al.. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA. 1997
Lee DC, Schlienz NJ, Herrmann ES et al.. Randomized controlled trial of zolpidem as a pharmacotherapy for cannabis use disorder. Journal of substance use and addiction treatment. 2024
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack